TransMedics Q1 revenue up 21% but net income plunges 71% YoY; guidance reiterated

TransMedics Group, Inc.

2026-Q1 EPS reported $0.20 revenue$173,933,000

Revenue $173.9M (+21% YoY); net income $7.3M ($0.20 diluted EPS), down 71% from $0.70.
Adjusted net income $10.9M ($0.30 diluted EPS), down 59% YoY.
Operating margin 7.6% vs 19.1% prior year; adjusted operating margin 10.4%.
Reiterates FY 2026 revenue guidance $727M-$757M.
Announced investment in PAD Aviation to create European transplant logistic network; owns 22 aircraft.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported the quarter ended March 31, 2026 results: revenue $173.9 million, net income $7.3 million, EPS $0.20 per fully diluted share. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: $173.9 million
Net income: $7.3 million
EPS: $0.20 per fully diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025 ▪ Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026

View on SEC.gov

Browse all earnings releases →

TransMedics Group, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-206347

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.